Hints and tips:
Related Special Reports
...Ryan Richardson, chief strategy officer at BioNTech, said the company was focused on the mid-to-long term and that most of the shareholders were long-term investors....
...Mr Richardson added that the company had invested more than $1bn to develop its innovative mRNA technology platform....
...Rival biotech group Intellia Therapeutics plans to seek US approval for its own trial in the second half of 2020....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...According to Ben Shepherd, director of therapeutics at Organovo, the challenges ahead are about increasing the size of the tissue that can be grown....
...My head is covered by an enormous plastic helmet-come-halo and a fine mist is rising from the contraption, writes Libby Richardson....
International Edition